Literature DB >> 7298065

[Human normal immunoglobulin, requirements for its safety and potency (author's transl)].

W Schneider, P E Kaiser.   

Abstract

On the basis of the official requirements for human normal immunoglobulin established by the European Pharmacopoeia, the immunoglobulins for intramuscular and intravenous use are described and analyzed. According to manufacturers processing by enzymatic digestion, chemical or other treatment the immunoglobulins, for intravenous use show differences in their composition, especially in regards to the distribution of aggregates, monomers and fragments of immunoglobulins and their subclass composition as well as their anticomplementary activity. Relative to the antibody content, the majority of the preparations show minor differences, only in an immunoglobulin of placental origin the content of tetanus antibodies was very low.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7298065

Source DB:  PubMed          Journal:  Immun Infekt


  2 in total

1.  Detection of antibodies to HTLV-III in commercially available immunoglobulin preparations.

Authors:  R Kurth; I Schmidt; A Werner; G von Wangenheim; J Löwer; H D Brede
Journal:  Klin Wochenschr       Date:  1986-04-15

2.  [Effect of adjuvant immunoglobulin therapy on infections in patients in an surgical intensive care unit. Results of a randomized controlled study].

Authors:  H M Just; M Metzger; W Vogel; R B Pelka
Journal:  Klin Wochenschr       Date:  1986-03-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.